Linguistic Validation of the Free and Cued Selective Reminding Test with Immediate Recall (FCSRT-IR) in 3 Languages for 3 Countries with Alzheimer's Disease Patients
Mary C. Gawlicki, MBA; Shawn McKown, MA; Elizabeth Yohe Moore, MPH; Barbara Brandt, MA
Corporate Translations, Inc.; East Hartford, CT; Chicago, IL; USA

OBJECTIVE
The objective of this study was to translate and linguistically validate the Free and Cued Selective Reminding Test with Immediate Recall (FCSRT-IR) to 3 languages for 3 countries with Alzheimer’s disease patients. Linguistic validation of the FCSRT-IR involved an interdisciplinary team of medical professionals, native speakers, and a project manager. This team reviewed the FCSRT-IR’s comprehension and cultural appropriateness, making appropriate revisions. This process was critical to ensure that the test was culturally appropriate and linguistically validated for use in other languages.

BACKGROUND
The FCSRT-IR is an instrument used in a cognitive assessment battery to test memory function in Alzheimer's disease patients. The FCSRT-IR is a clinician-administered test with requirements for immediate recall and cued recall.

METHODS
The FCSRT-IR consists of identification and naming of words that appear on a card with immediate cued recall, free recall after a 20-second interference task, and then another cued recall of any words forgotten during the free recall task. This protocol was translated and linguistically validated to 3 languages: Italian, Spanish, and Portuguese.

RESULTS
Of the 13 translation revisions, 11 of these were made in favor of an alternative term that was agreed upon by the translators. Two revisions were made due to cultural inappropriateness for the target language and country.

CONCLUSION
The FCSRT-IR successfully completed linguistic validation with patients who have mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD). It was considered linguistically validated for use in 3 countries with 3 languages.

REFERENCES
2. Brachman B. Cued selection with immediate recall (FCSRT-IR) with mild cognitive impairment (MCI) and mild Alzheimer's disease (AD). Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting, May 21-25, 2016; Washington DC, USA.